BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Bioinformatics Software | QIAGEN Digital Insights - ECPv6.15.17.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://staging.digitalinsights.supremeclients.com
X-WR-CALDESC:Events for Bioinformatics Software | QIAGEN Digital Insights
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20220101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=UTC:20231012T100000
DTEND;TZID=UTC:20231012T120000
DTSTAMP:20260411T045207
CREATED:20230912T164947Z
LAST-MODIFIED:20241024T182938Z
UID:10000685-1697104800-1697112000@staging.digitalinsights.supremeclients.com
SUMMARY:Part 1: AI-Powered Hereditary Disease Diagnostics: Closing the Gap in Clinical Exome Completeness
DESCRIPTION:Clinical exome sequencing (CES) is increasingly being adopted by small and mid-sized laboratories to diagnose genetic diseases\, aid treatment decisions\, and provide prognostic information. However\, the exponential increase in genetic data generated from exome and genome panels poses significant workflow challenges. The ability to prioritize potentially pathogenic variants from large datasets and identify the few candidate variants becomes more difficult. This issue is further amplified in cases where labs must use deep phenotyping of patients and compare that to reference genotype-phenotype knowledge associated with each candidate variant. To overcome these challenges\, labs are beginning to implement Artificial Intelligence (AI) in their variant analysis\, interpretation and reporting workflows. \nJoin us for our 2023 Clinical Hereditary Disease Diagnostics Summit\, a free-to-attend\, two-part event exploring the opportunities and limitations of AI in hereditary disease diagnostics. Designed to help clinical diagnostic labs learn how to safely apply AI to exome and genome sequencing workflows\, the content-rich event will feature invited lectures from lab directors and clinical geneticists\, thought-provoking discussions on the future of hereditary disease diagnostics\, as well as educational presentations on the latest databases and AI-powered software for germline secondary and tertiary analysis. \nPart I: Educational talks – October 12\, 2023 \nAn education session exploring the latest databases\, software\, and services for germline secondary and tertiary NGS analysis. Topics will include: \n\nHow labs can achieve clinical exome completeness with AI-enriched and manually curated content\nHow labs can apply enhanced phenotype-driven ranking in clinical cases\nHow labs can safely use a “smart” approach to AI to reach the best possible chance of reaching a diagnosis
URL:https://staging.digitalinsights.supremeclients.com/webinars-and-events/part-1-ai-powered-hereditary-disease-diagnostics-closing-the-gap-in-clinical-exome-completeness/
LOCATION:Virtual Global Event (Times shown in EST)
CATEGORIES:Clinical,Training
ATTACH;FMTTYPE=image/jpeg:https://staging.digitalinsights.supremeclients.com/wp-content/uploads/2024/05/S_1325_0_QDI_QCI_HGMD_blog_Gi1346512014.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231012T130000
DTEND;TZID=America/New_York:20231012T143000
DTSTAMP:20260411T045207
CREATED:20230912T144219Z
LAST-MODIFIED:20241024T182932Z
UID:10000675-1697115600-1697121000@staging.digitalinsights.supremeclients.com
SUMMARY:Exploring pan-cancer immunomodulators for biomarker discovery and validation using TCGA and public single-cell data
DESCRIPTION:Cancer outcome is influenced by both the tumor microenvironment and host immune response. Using QIAGEN OmicSoft Studio to access public data from The Cancer Genome Atlas (TCGA) and our human Single Cell Lands collection\, you’ll learn how to:\n• View host immune response clusters across TCGA samples\n• Identify differentially expressed immunomodulators across sample groups\n• Visualize single-cell dimension reduction maps and overlay expression data\n• Identify potential biomarkers whose expression correlates or anti-correlates with target genes\n• Validate new biomarkers using custom queries and TCGA survival data
URL:https://staging.digitalinsights.supremeclients.com/webinars-and-events/exploring-pan-cancer-immunomodulators-for-biomarker-discovery-and-validation-using-tcga-and-public-single-cell-data/
LOCATION:Virtual - Americas - EST\, United States
CATEGORIES:Discovery,Webinar
ATTACH;FMTTYPE=image/jpeg:https://staging.digitalinsights.supremeclients.com/wp-content/uploads/2024/05/S_9308_BIOX_OmicSoft_Gi576919878_V2_Large-1200px_47746.jpg
END:VEVENT
END:VCALENDAR